Last updated: May 21, 2026
Delatestryl clinical trials update and market projection (HCG, testosterone replacement-related uses)
Executive summary
- Drug: Delatestryl (brand name for chorionic gonadotropin (hCG); marketed in the US as an injectable).
- Clinical-trial update: No current, clearly identifiable active clinical-trial readouts or late-stage registrational studies tied specifically to Delatestryl (as opposed to generic hCG products) can be confirmed from the publicly indexed trial record set available in this workspace.
- Market analysis and projection: A reliable, single-drug Delatestryl-specific revenue projection cannot be produced without a product-level price and unit-sales baseline (brand share vs. generic hCG share, tender/contract mix, and geographic reimbursement dynamics), which is not present in the available data in this workspace.
What is Delatestryl (chorionic gonadotropin) used for clinically?
Delatestryl is an hCG injectable used in endocrine and fertility contexts. hCG is used to induce or support gonadal function, and it is used in specific hypogonadism and fertility protocols depending on region, indication, and formulation.
Which FDA-labeled indications typically apply to hCG products like Delatestryl?
For hCG injectable products, labeled uses commonly include:
- Male hypogonadotropic hypogonadism (as part of gonadotropin replacement regimens).
- Induction of spermatogenesis in selected settings.
- Assisted reproduction protocols (context depends on local label and clinical protocol).
(Exact Delatestryl US label text and indication list must match the product label; that label text is not available in this workspace.)
What clinical trials are ongoing for Delatestryl right now?
No Delatestryl-specific ongoing clinical trial set with current recruitment status, primary endpoints, or near-term readout dates can be verified from the available indexed materials in this workspace.
Do trials studying hCG apply to Delatestryl’s commercial outlook?
- Clinical evidence on hCG as an active ingredient generally informs clinician use and guideline inclusion.
- Commercial impact depends on whether the trial enrollment, payer coverage, and procurement pathway favors brand Delatestryl versus unbranded/generic chorionic gonadotropin injection.
- Without product-level enrollment patterns and formulary/contract preferences, mapping trial activity to Delatestryl revenue is not actionable.
When do Delatestryl patents or exclusivity expire and how does that affect generic entry?
A Delatestryl exclusivity and patent-expiration timeline cannot be constructed here because patent and Orange Book listing data for Delatestryl are not present in the available workspace content.
What is the Paragraph IV / generic entry risk for Delatestryl?
Paragraph IV risk analysis requires:
- Orange Book patent identification for the Delatestryl NDA,
- applicant ANDA status, and
- any pending certifications and litigation.
Those data are not available in this workspace.
What is the Orange Book status of Delatestryl and which patents cover the product?
Orange Book status and patent coverage cannot be enumerated without:
- NDA identifier(s),
- listed patents and patent expiration dates,
- exclusivity codes tied to the product.
This information is not present in this workspace.
How strong is the patent estate for Delatestryl, formulation by formulation?
A strength assessment requires:
- claim scope by patent family,
- expiration dates and terminal disclaimers,
- whether patents cover drug substance, formulation, method of use, and manufacturing.
No Delatestryl patent family list is available here.
What patent litigation affects Delatestryl and its potential generic competitors?
Litigation status requires:
- case dockets tied to the Delatestryl NDA/Orange Book patents,
- settlements, consent decrees, and generic launch triggers.
No litigation dataset for Delatestryl is in this workspace.
Which companies manufacture or market Delatestryl and how concentrated is supply?
Company and supply concentration analysis requires:
- current market authorizations by geography,
- manufacturer list for the brand and key generics,
- procurement structure (hospital vs wholesale).
This data is not present in this workspace.
How does Delatestryl compare with competing hCG products in efficacy, safety, and dosing?
A defensible comparison requires:
- head-to-head clinical evidence or accepted bioequivalence standards,
- labeled dosing regimens (IU per vial) and administration schedules,
- substitution equivalence in formularies.
No Delatestryl product specification, dosing label, or comparator product list is available in this workspace.
Are there delivery-system or strength differences that affect substitution?
hCG injection products vary by:
- vial strength (IU per dose),
- solvent/vehicle,
- labeling and storage conditions.
Without Delatestryl-specific strengths and comparator mappings, substitution-risk assessment cannot be made.
What is the FDA regulatory pathway status for Delatestryl (NDA vs ANDA vs RLD)?
A pathway map requires:
- NDA and RLD identifiers,
- ANDA listing records,
- latest supplements and manufacturing changes.
This information is not included in this workspace.
How is the Delatestryl market trending and what drives demand?
Demand drivers for hCG injectables generally include:
- fertility-treatment utilization and cycle counts,
- male hypogonadism management patterns,
- payer coverage for endocrine and reproductive indications,
- competition from generic hCG products.
However, Delatestryl-specific trend drivers (brand vs generic share, tender wins, and payer mix) cannot be quantified here.
Market projection for Delatestryl: base, bull, and bear scenarios
A Delatestryl projection requires at least:
- current annual US (and ex-US) net sales,
- brand share and estimated generic displacement curve,
- pricing trend and rebate/tender terms,
- expected entry/launch timing from ANDA filings and patent sunsets,
- utilization forecast for labeled indications.
Those inputs are not available in this workspace, so a credible projection cannot be produced.
What would a scenario model require at minimum?
- Baseline: current Delatestryl unit sales and ASP net of rebates.
- Forecast: generic penetration and substitution velocity.
- Risk: supply disruptions and manufacturing compliance events.
- Mix: fertility protocol adoption rates and endocrine guideline shifts.
No such baseline or forecast parameters are present in this workspace.
Key Takeaways
- Delatestryl is an hCG injectable product, but a Delatestryl-specific clinical-trial update and revenue projection cannot be validated from the available workspace inputs.
- Patent-exclusivity status, Orange Book coverage, litigation, and generic-entry scenarios also cannot be reliably enumerated without Delatestryl listing and case record data.
FAQs
1) What indications does Delatestryl cover in the US label?
Not determinable from the available workspace content.
2) Are there ongoing Phase 3 trials for Delatestryl itself?
Not determinable from the available workspace content.
3) How do generic chorionic gonadotropin injections affect Delatestryl pricing and access?
Not quantifiable here without brand/generic market-share data.
4) What patents protect Delatestryl and when do they expire?
Not determinable here without Orange Book listing data.
5) What litigation history involves Delatestryl generics?
Not determinable here without docket-level litigation data.
References
- No citable source material is present in the available workspace for Delatestryl-specific trials, Orange Book listings, or litigation.
